Literature DB >> 6859941

Management of the extrapyramidal manifestations of phenylketonuria with L-dopa.

M D MacLeod, J F Munro, J G Ledingham, J W Farquhar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6859941      PMCID： PMC1627972          DOI： 10.1136/adc.58.6.457

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  3 in total

Review 1.  PHENYLKETONURIA IN PEDIATRIC PRACTICE.

Authors:  J W FARQUHAR; J RICHMOND; H P TAIT
Journal:  Clin Pediatr (Phila)       Date:  1963-09       Impact factor: 1.168

2.  The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria).

Authors:  R S PAINE
Journal:  Pediatrics       Date:  1957-08       Impact factor: 7.124

3.  Pathogenesis of phenylketonuria: inhibition of DOPA and catecholamine synthesis in patients with phenylketonuria.

Authors:  H C Curtius; K Baerlocher; J A Völlmin
Journal:  Clin Chim Acta       Date:  1972-11       Impact factor: 3.786
  3 in total
  1 in total

1.  Clinical and neuropsychological outcomes for children with phenylketonuria in Upper Egypt; a single-center study over 5 years.

Authors:  Abdelrahim A Sadek; Mohammed H Hassan; Nesreen A Mohammed
Journal:  Neuropsychiatr Dis Treat       Date:  2018-10-05       Impact factor: 2.570
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.